Benzinga | Aug 24, 2021 06:13AM EDT

HC Wainwright & Co. Maintains Buy on Cara Therapeutics, Raises Price Target to $35

HC Wainwright & Co. analyst Oren Livnat maintains Cara Therapeutics (NASDAQ:CARA) with a Buy and raises the price target from $33 to $35.